Clinical trial
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00068029 |
|---|---|
| Title | Pegvisomant And Sandostatin LAR Combination Study |
| Official title | A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant |
| Enrollment | 75 |
| Start date | Oct 1, 2003 |
| Completion | May 1, 2006 |
| First posted | Sep 5, 2003 |
| Last update posted | Apr 7, 2008 |
| Countries | Australia, Brazil, Canada, France, Germany, Italy, Mexico, Netherlands, Norway, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: